Nature Communications (Jun 2018)
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
- Ali Talebi,
- Jonas Dehairs,
- Florian Rambow,
- Aljosja Rogiers,
- David Nittner,
- Rita Derua,
- Frank Vanderhoydonc,
- Joao A. G. Duarte,
- Francesca Bosisio,
- Kathleen Van den Eynde,
- Kris Nys,
- Mónica Vara Pérez,
- Patrizia Agostinis,
- Etienne Waelkens,
- Joost Van den Oord,
- Sarah-Maria Fendt,
- Jean-Christophe Marine,
- Johannes V. Swinnen
Affiliations
- Ali Talebi
- Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- Jonas Dehairs
- Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- Florian Rambow
- Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology
- Aljosja Rogiers
- Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology
- David Nittner
- Histopathology Expertise Center, VIB-KU Leuven Center for Cancer Biology
- Rita Derua
- Laboratory of Protein Phosphorylation and Proteomics,Department of Cellular and Molecular Medicine, KU Leuven
- Frank Vanderhoydonc
- Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- Joao A. G. Duarte
- Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- Francesca Bosisio
- Translational Cell and Tissue Research, Department of Imaging and Pathology
- Kathleen Van den Eynde
- Translational Cell and Tissue Research, Department of Imaging and Pathology
- Kris Nys
- Laboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven
- Mónica Vara Pérez
- Laboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven
- Patrizia Agostinis
- Laboratory of Cell Death Research & Therapy, Department of cellular and molecular medicine, KU Leuven
- Etienne Waelkens
- Laboratory of Protein Phosphorylation and Proteomics,Department of Cellular and Molecular Medicine, KU Leuven
- Joost Van den Oord
- Translational Cell and Tissue Research, Department of Imaging and Pathology
- Sarah-Maria Fendt
- Laboratory of Cellular Metabolism and Metabolic Regulation, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- Jean-Christophe Marine
- Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology
- Johannes V. Swinnen
- Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI–Leuven Cancer Institute, KU Leuven
- DOI
- https://doi.org/10.1038/s41467-018-04664-0
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma.
